George Perry (University of Texas at San Antonio [UTSA], San Antonio, TX), a valued member of our editorial board for US Neurology, discusses therapeutic targets in Alzheimer’s disease with a particular focus on the role of oxidative stress in the underlying pathophysiology of the disease.
1. Why do you think so many Alzheimer’s disease (AD) therapies have failed in phase III clinical studies? (0:09)
2. What are the most promising alternative therapeutic targets under investigation? (0:54)
3. What is the role of oxidative stress in the pathophysiology of AD? (1:49)
4. What is the main intracellular source of oxidative stress in AD? (2:36)
5. How can oxidative stress and mitochondria be targeted therapeutically? (3:17)
Speaker disclosure: George Perry serves as an advisor for Investicure and Phoenix Biotech, and is a board member for Neurotez and Neurotrope.
Filmed during a video call with Editorial Board member George Perry from his office at the University of Texas at San Antonio (UTSA), San Antonio, TX, US, July 2018.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Yona Levites, AD/PD 2021: Immunotherapeutic Approaches in Alzheimer’s Disease (Part 1)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!